Society for Immunotherapy of Cancer: Celyad presenteert klinische updates CYAD-01 voor solide tumoren en preklinische pipeline-gegevens

Celyad’s pipeline toegelicht via presentatie en posters

Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussel en Parijs, en NASDAQ: CYAD), een klinisch biofarmaceutisch bedrijf dat zich richt op de ontwikkeling van celgebaseerde CAR-T behandelingen, kondigde vandaag aan dat klinische en preklinische pipeline-gegevens gepresenteerd zullen worden op de jaarlijkse bijeenkomst van de Society for Immunotherapy of Cancer (SITC) van 7 tot 11 november 2018 in Washington, D.C. Het programmacomité van SITC heeft niet minder dan tien verschillende abstracts van Celyad geselecteerd die getuigen van het krachtig en ambitieus onderzoeksprogramma van de firma.

“SITC 2018 is een belangrijke bijeenkomst”, aldus David Gilham, Ph.D., VP Research and Development bij Celyad. “Ten eerste zullen we een klinische update geven van ons CYAD-01 programma in solide tumoren. Ten tweede zullen we aangeven hoe we onze academische asset, met name de NKG2D CAR-T-cellen, verder hebben doen uitgroeien tot de commercieel haalbare klinische entiteit CYAD-01. We zullen ook een update geven over onze CAR-T-pipeline van de volgende generatie, en in het bijzonder over ons niet-genbewerkte allogeen CAR-T-programma. We denken dat we in de komende jaren een leidende rol zullen spelen in het domein van de autologe en allogene CAR-T celtherapie.”

Mondeling presentatie:

Abstract P213: CYAD-101: an allogeneic NKG2D CAR-T cell therapy using a TCR inhibitory molecule
Datum: 9 november, 14u00 – 14u05
Sessie: Rapid Oral Abstracts
Posters:

Abstract P218:  
Endogenous DAP10 provides optimal co-stimulation to NKG2D-based CAR-T cells  
Datum: 10 november, 12u20 – 13u50 en 19u00 – 20u30  
Sessie: Cellular Therapy Approaches

Abstract P220:  
Generating Allogeneic CAR-T cells without Gene Editing  
Datum: 10 november, 12u20 – 13u50 en 19u00 – 20u30  
Sessie: Cellular Therapy Approaches

Abstract P221:  
The co-expression of a single shRNA targeting MICA and MICB with a NKG2D CAR (CYAD-01) generates CAR-T cells resistant to target driven fratricide and improves CYAD-01 cell persistence in vivo  
Datum: 9 november, 12u45 – 14u15 en 18u30 – 20u00  
Sessie: Cellular Therapy Approaches

Abstract P231:  
Uncovering the phenotype, the functional and homing properties of NKG2D CAR-T cells  
Datum: 9 november, 12u45 – 14u15 en 18u30 – 20u00  
Sessie: Cellular Therapy Approaches

Abstract P232:  
Differential effects of target ligands upon NKG2D CAR-T cell activation  
Datum: 10 november, 12u20 – 13u50 en 19u00 – 20u30  
Sessie: Cellular Therapy Approaches

Abstract P255:  
Results and perspectives from Phase 1 studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, in metastatic solid tumors  
Datum: 9 november, 12u45 – 14u15 en 18u30 – 20u00  
Sessie: Cellular Therapy Approaches

Abstract P274:  
Functional screening of different anti-B7H6 CAR designs  
Datum: 10 november, 12u20 – 13u50 en 19u00 – 20u30  
Sessie: Cellular Therapy Approaches

Abstract P275:  
Pooling signaling and costimulatory domains in a flexible CARpool design  
Datum: 9 november, 12u45 – 14u15 en 18u30 – 20u00  
Sessie: Cellular Therapy Approaches
Abstract P626: Overcoming target-driven fratricide for CAR-T cell therapy
Datum: 10 november, 12u20 – 13u50 en 19u00 – 20u30
Sessie: Other

About Celyad
Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based therapies. Celyad utilizes its expertise in cell engineering to target cancer. Celyad’s CAR-T cell platform has the potential to treat a broad range of solid and hematologic tumors. Its lead oncology candidate, CYAD-01 (CAR-T NKG2D), is currently evaluated in a Phase I dose escalation clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematologic tumors (acute myeloid leukemia and multiple myeloma). The safety and clinical activity of the CYAD-01 therapy concurrently administered with standard-of-care treatments or preconditioning chemotherapy is also assessed in a full clinical development program focused on acute myeloid leukemia and colorectal cancer. Celyad was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and New York, NY. Celyad’s ordinary shares are listed on the Euronext Brussels and Euronext Paris exchanges, and its American Depositary Shares are listed on the NASDAQ Global Market, all under the ticker symbol CYAD.

For more information, please contact:

Celyad
investors@celyad.com
Filippo Petti, Chief Financial Officer
communications@celyad.com
Carri Duncan, VP Corporate Development & Communications - T: +32(0) 10 39 41 87

For Belgium: Comfi
Sabine Leclercq - T.: +32 (0)2 290 90 91 - celyad@comfi.be

For France: NewCap
Pierre Laurent and Nicolas Mérigeau - T: +33(0)1 44 71 94 94 - celyad@newcap.eu

For the U.S.: LifeSci Advisors
Daniel Ferry - T.: +1 (617) 535 7746 - daniel@lifesciadvisors.com
Public Relations: Allison Blum - T:+1 (646) 627 8383 - allison@lifescipublicrelations.com
Forward-looking statements

This release may contain forward-looking statements, including statements regarding the safety and efficacy of CYAD-01 and the new mAb manufacturing method used to manufacture this drug product candidate; statements concerning the ongoing and planned clinical development of CYAD-01, including the timing of data readouts and presentations; the clinical and commercial potential of CYAD-01 and the adequacy of Celyad’s financial resources; Celyad’s financial condition, results of operation and business outlook; and Celyad’s expected cash burn. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual results, financial condition and liquidity, performance or achievements of Celyad, or industry results, to differ materially from those expressed or implied by such forward-looking statements. In particular it should be noted that the interim data summarized above are preliminary in nature. There is limited data concerning safety and clinical activity following treatment with the CYAD-01 drug product candidate. These results may not be repeated or observed in ongoing or future studies involving the CYAD-01 drug product candidate. These forward-looking statements are further qualified by important factors and risks, which could cause actual results to differ materially from those in the forward-looking statements, including statements about: the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our ability to advance drug product candidates into, and successfully complete, clinical trials; our ability to successfully manufacture drug product for our clinical trials, including with our new mAb manufacturing process and with respect to manufacturing drug product with the desired number of T cells under our clinical trial protocols; our reliance on the success of our drug product candidates, including our dependence on the regulatory approval of CYAD-01 in the United States and Europe and subsequent commercial success of CYAD-01, both of which may never occur; the timing or likelihood of regulatory filings and approvals; our ability to develop sales and marketing capabilities; the commercialization of our drug product candidates, if approved; the pricing and reimbursement of our drug product candidates, if approved; the implementation of our business model, strategic plans for our business, drug product candidates and technology; the scope of protection we are able to establish and maintain for intellectual property rights covering our drug product candidates and technology; our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights and proprietary technology of third parties; cost associated with enforcing or defending intellectual property infringement, misappropriation or violation; product liability; and other claims; regulatory development in the United States, the European Union, and other jurisdictions; estimates of our expenses, future revenues, capital requirements and our needs for additional financing; the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements; our ability to maintain and establish collaborations or obtain additional grant funding; the rate and degree of market acceptance of our drug product candidates, if approved; our financial performance; developments relating to our competitors and our industry, including competing therapies and statements regarding future revenue, hiring plans, expenses, capital expenditures, capital requirements and share performance. A further list and description of these risks, uncertainties and other risks can be found in Celyad’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in its Annual Report on Form 20-F filed with the SEC on April 6, 2018 and subsequent filings and reports by Celyad. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document and Celyad’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.